Our founders were pioneers of monoclonal antibody therapy, bringing to the clinic the first humanised antibody, the first made in CHO cells, the first bispecific and the first aglycosylated antibody. Now we have developed a new Fc variant which is more comprehensively silenced than previous antibodies. It is able to reduce unwanted inflammatory responses from the next generation of antibody-based drugs. We are building partnerships with Universities, Biotech and Pharma companies to make this new technology widely available.
| Website | https://mabsolve.com |
| Employees | 6 (2 on RocketReach) |
| Founded | 2019 |
| Technologies |
HTML
,
PHP
,
Font Awesome
+7 more
(view full list)
|
| Industry | Biotechnology Research |
| Keywords | Clinical Stage, Preclinical Development, Biopharmaceutical, Biotechnology, Pharmaceutical Development, Therapeutic Antibodies, Immunotherapy, Protein Engineering, Drug Development, Biologics, Antibody Engineering, Pharmaceutical Manufacturing, Bioprocessing, Drug Discovery |
| Competitors | Johnson & Johnson, Roche, AbbVie, Pfizer, Sanofi, AstraZeneca, Bristol Myers Squibb, Genentech, Amgen, Lilly India +47 more (view full list) |
Looking for a particular mAbsolve employee's phone or email?
mAbsolve Questions
Geoff Hale is the CEO of mAbsolve.
2 people are employed at mAbsolve.
Top mAbsolve Employees
Related Companies
